Document is current
Any future updates will be listed below
-
Authors
Zhang, Yifan https://orcid.org/0009-0001-1106-8911
Xu, Xiaomin
Wang, Shulin
Yin, Xiaochen
Zhang, Bohan
Zhu, Zhengnong
Ji, Rujie
Zhu, Jing
He, Hermione
Cheng, Siyuan
Han, Zihan
Xie, Tong
Zhang, Xiaotian
Wang, Yakun
Shen, Si
Kou, Yan
Bao, Siyu
Liu, Yingyu
Cao, Baoran
Bonny, Christophe
Guo, Xiaohuan
Segal, Eran
Tan, Yan
Shen, Lin https://orcid.org/0000-0003-1134-2922
Peng, Zhi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04130763 at ClinicalTrials.govnct04130763 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.
https://doi.org/10.1200/jco.2023.41.4_suppl.389
The role of gut microbiota in cancer treatment: friend or foe?
https://doi.org/10.1136/gutjnl-2020-321153
Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study
https://doi.org/10.1136/jitc-2025-013823
nct04130763 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.
https://doi.org/10.1200/jco.2023.41.4_suppl.389
The role of gut microbiota in cancer treatment: friend or foe?
https://doi.org/10.1136/gutjnl-2020-321153
Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study
https://doi.org/10.1136/jitc-2025-013823
Documents that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.
https://doi.org/10.1200/jco.2023.41.4_suppl.389
The role of gut microbiota in cancer treatment: friend or foe?
https://doi.org/10.1136/gutjnl-2020-321153
Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study
https://doi.org/10.1136/jitc-2025-013823
-
Funding
Funding for this research was provided by:
Xbiome (N/A)
Natural Science Foundation of Beijing Municipality (L244026)
National Natural Science Foundation of China (General Program (2019-1)
National Natural Science Foundation of China (General Program (82272764)
Key Program of Beijing Natural Science Foundation (Z210015)
- License Information
